A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.

Ingrid K Hals Chandima N D Balasuriya Rosaura Casas Johnny Ludvigsson Anneli Björklund Valdemar Grill

Published in: Diabetes, obesity & metabolism (2023)

Intralymphatic treatment with GAD-alum in LADA is without clinical or other safety concerns over a 12-month period. As in a similar protocol used in type 1 diabetes, treatment exerts a strong immunological impact and is compatible with protection of beta-cell function preferentially in HLA-DR3DQ2 LADA patients. These findings pave the way for a randomized controlled trial in this important subgroup of LADA patients.

Keyphrases

type diabetes
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
cardiovascular disease
glycemic control
peritoneal dialysis
randomized controlled trial
multiple sclerosis
clinical trial
patient reported outcomes
replacement therapy
platelet rich plasma
double blind